Breaking News

Breaking News English

Urgent::www.AMUNetwork.com needs Part Time campus Reporters.Please Contact:-deskamunetwork@gmail.com
Prof. Tariq Mansoor is presently serving as the Vice-Chancellor, Aligarh Muslim University, Aligarh. Previously he has also served as Principal, J.N. Medical College, Chief Medical Superintendent, J.N. Medical College Hospital and Chairman, Department of Surgery. He is also the member of Medical Council of India since March 2015 for a period of four years. He is product of the first batch of prestigious Our Lady of Fatima Higher Secondary School, Aligarh. During his school days he has served as House Captain as well as School Captain. He did his MBBS and MS in General Surgery from Jawaharlal Nehru Medical College, AMU, Aligarh. A surgeon by profession with special interest in Breast and Thyroid Diseases, Prof. Tariq Mansoor has 33 years of Teaching and 35 years of Clinical experience. He has 90 publications to his credit and has guided 49 Postgraduate Medical Students for their Thesis as Supervisor / Co-Supervisor

New test offers hope for Alzheimer’s sufferers

New test offers hope for Alzheimer’s sufferers

Washington: Seems like, a new blood test can be useful to detect people at risk of developing Alzheimer’s disease.

According to a Ruhr University Bochum-led study, the new blood test for Alzheimer’s disease can detect early indicators of the disease long before the first symptoms appear in patients.

The blood test would, thus, offer an opportunity to identify those at risk and may thereby open the door to new avenues in drug discovery.

There is, as yet, no cure for Alzheimer’s disease. It is often argued that progress in drug research has been hampered by the fact that the disease can only be diagnosed when it is too late for an effective intervention. Alzheimer’s disease is thought to begin long before patients show typical symptoms like memory loss.

One of the hallmarks of Alzheimer’s disease is the accumulation of amyloid-beta plaques in the patient’s brain.

The blood test, developed by Klaus Gerwert and his team worked by measuring the relative amounts of a pathological and a healthy form of amyloid-beta in the blood. The pathological form is a misfolded version of this molecule and known to initiate the formation of toxic plaques in the brain. Toxic amyloid-beta molecules start accumulating in the patients’ body 15-20 years before disease onset.

They found that the test reliably detected amyloid-beta alterations in the blood of participants with a mild cognitive impairment that also showed abnormal amyloid deposits in brain scans.

Currently available diagnostic tools for Alzheimer’s disease either involve expensive positron emission tomography (PET) brain scans or analyze samples of cerebrospinal fluid that are extracted via lumbar puncture.

The researchers suggested that their blood test served as a cheap and simple option to pre-select individuals from the general population for further testing by these more invasive and costly methods to exclude the falsely positive subjects.

The findings from the study are published in the journal EMBO Molecular Medicine. (ANI)

Read More

from The Siasat Daily

No comments:

Post a Comment